BR112016001948A2 - antagonistas de v1a para tratar distúrbios do sono de desvio de fase - Google Patents

antagonistas de v1a para tratar distúrbios do sono de desvio de fase

Info

Publication number
BR112016001948A2
BR112016001948A2 BR112016001948A BR112016001948A BR112016001948A2 BR 112016001948 A2 BR112016001948 A2 BR 112016001948A2 BR 112016001948 A BR112016001948 A BR 112016001948A BR 112016001948 A BR112016001948 A BR 112016001948A BR 112016001948 A2 BR112016001948 A2 BR 112016001948A2
Authority
BR
Brazil
Prior art keywords
phase shift
sleep disorders
antagonists
shift sleep
relates
Prior art date
Application number
BR112016001948A
Other languages
English (en)
Inventor
Grundschober Christophe
Schnider Patrick
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112016001948A2 publication Critical patent/BR112016001948A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)

Abstract

esta invenção refere-se a um novo uso médico para certos compostos químicos e composições farmacêuticas que os contêm. a invenção refere-se aos compostos que são antagonistas de v1a, sele-tivos para uso no tratamento de distúrbios do sono de desvio de fase, em particular descompensação horária. em outro aspecto, a invenção refere-se a uma composição farmacêutica para uso no tratamento de distúrbios do sono de desvio de fase compreendendo um composto de acordo com a invenção e um veículo farmaceuticamente aceitável.
BR112016001948A 2013-08-19 2014-08-12 antagonistas de v1a para tratar distúrbios do sono de desvio de fase BR112016001948A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13180836 2013-08-19
PCT/EP2014/067264 WO2015024819A1 (en) 2013-08-19 2014-08-12 V1a antagonists to treat phase shift sleep disorders

Publications (1)

Publication Number Publication Date
BR112016001948A2 true BR112016001948A2 (pt) 2017-08-01

Family

ID=48985673

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016001948A BR112016001948A2 (pt) 2013-08-19 2014-08-12 antagonistas de v1a para tratar distúrbios do sono de desvio de fase

Country Status (21)

Country Link
US (1) US10265327B2 (pt)
EP (1) EP3035939B1 (pt)
JP (1) JP6427192B2 (pt)
KR (1) KR20160042903A (pt)
CN (1) CN105492010B (pt)
AU (1) AU2014310733A1 (pt)
BR (1) BR112016001948A2 (pt)
CA (1) CA2919738A1 (pt)
CL (1) CL2016000325A1 (pt)
CR (1) CR20160042A (pt)
EA (1) EA201690179A1 (pt)
ES (1) ES2793929T3 (pt)
HK (1) HK1217171A1 (pt)
IL (1) IL243387A0 (pt)
MA (1) MA38867A1 (pt)
MX (1) MX2016001940A (pt)
PE (1) PE20160203A1 (pt)
PH (1) PH12016500124A1 (pt)
PL (1) PL3035939T3 (pt)
SG (1) SG11201600991QA (pt)
WO (1) WO2015024819A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6454707B2 (ja) 2013-12-05 2019-01-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ｔｒａｎｓ−８−クロロ−５−メチル−１−［４−（ピリジン−２−イルオキシ）−シクロヘキシル］−５，６−ジヒドロ−４Ｈ−２，３，５，１０ｂ−テトラアザ−ベンゾ［ｅ］アズレン及びその結晶形態の合成
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
WO2018133835A1 (en) * 2017-01-20 2018-07-26 National Institute Of Biological Sciences, Beijing Nucleoside analogue regulating mammalian circadian rhythm
KR20200097702A (ko) * 2017-12-08 2020-08-19 에프. 호프만-라 로슈 아게 약학 제형
EP4185570A1 (en) * 2020-07-23 2023-05-31 F. Hoffmann-La Roche AG Cyclohexyl substituted triazoles as vasopressin receptor v1 a antagonists
JP2023534721A (ja) * 2020-07-23 2023-08-10 エフ． ホフマン－ラ ロシュ アーゲー バソプレシン受容体ｖ１ａアンタゴニストとしてのヘテロアリール－メチル置換トリアゾール

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1330451B1 (en) * 2000-10-27 2008-01-23 Ortho-McNeil Pharmaceutical, Inc. Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators
US20050107411A1 (en) * 2001-12-17 2005-05-19 Macneil Douglas J. Method for treating circadian rhythm disruptions
GB0303852D0 (en) * 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
MX2007002248A (es) * 2004-08-25 2008-10-02 Pfizer Triazolobenzodiazepinas y su uso como antagonistas de vasopresina.
ES2431279T3 (es) * 2008-11-28 2013-11-25 F. Hoffmann-La Roche Ag Arilciclohexiléteres de dihidro-tetraazabenzoazulenos para uso como antagonistas del receptor V1A de la vasopresina
JPWO2013176220A1 (ja) * 2012-05-25 2016-01-14 国立大学法人京都大学 概日リズム調整

Also Published As

Publication number Publication date
EP3035939A1 (en) 2016-06-29
JP6427192B2 (ja) 2018-11-21
SG11201600991QA (en) 2016-03-30
US20180064727A1 (en) 2018-03-08
ES2793929T3 (es) 2020-11-17
CL2016000325A1 (es) 2016-09-30
IL243387A0 (en) 2016-02-29
EP3035939B1 (en) 2020-03-25
MA38867A1 (fr) 2018-01-31
CA2919738A1 (en) 2015-02-26
MX2016001940A (es) 2016-06-02
AU2014310733A1 (en) 2016-02-04
KR20160042903A (ko) 2016-04-20
US10265327B2 (en) 2019-04-23
PH12016500124A1 (en) 2016-04-25
CN105492010B (zh) 2020-01-03
EA201690179A1 (ru) 2016-06-30
HK1217171A1 (zh) 2016-12-30
PE20160203A1 (es) 2016-04-20
WO2015024819A1 (en) 2015-02-26
JP2016528266A (ja) 2016-09-15
PL3035939T3 (pl) 2020-07-27
CN105492010A (zh) 2016-04-13
CR20160042A (es) 2016-04-01

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
BR112016001948A2 (pt) antagonistas de v1a para tratar distúrbios do sono de desvio de fase
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
GEP20207102B (en) Sulfonamides as modulators of sodium channels
ECSP14013325A (es) Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr)
CL2014000311A1 (es) Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
DOP2015000170A (es) Compuestos químicos
BR112013004850A2 (pt) tratamento de infarto do miocárdio usando antagonistas tgf-beta
UY31922A (es) Compuestos
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112014011254A2 (pt) 2-tiopirimidinonas
CL2014000819A1 (es) Compuestos heterociclicos derivados de etinilo, moduladores alostericos mglur5; proceso de preparacion; composicion farmaceutica; uso en la prevencion o el tratamiento de esquizofrenia, enfermedades cognitivas, sindrome de la x fragil o autismo.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI